Core Insights - Caris Life Sciences, Inc. is recognized for its advancements in precision medicine, utilizing whole exome and transcriptome sequencing alongside AI-driven insights for cancer detection and therapy selection [1] - The company reported significant growth in Q2 2025, with revenues reaching $181.4 million, an 81% increase year-over-year, and molecular profiling revenue rising nearly 86% [2] - Caris Life Sciences achieved profitability on an adjusted EBITDA basis, generating $16.7 million in EBITDA and $5.9 million in free cash flow, indicating strong investor confidence [2] Financial Performance - Q2 2025 revenue was $181.4 million, reflecting an 81% year-over-year growth [2] - Molecular profiling revenue increased by nearly 86% [2] - Gross margins improved to 62.7% from 37.5% a year ago [2] - The company completed over 50,000 clinical therapy selection cases [2] - Generated $16.7 million in adjusted EBITDA and $5.9 million in free cash flow [2] Scientific Advancements - Caris Life Sciences is enhancing its leadership in precision oncology, with recent findings on tumor-infiltrating clonal hematopoiesis (TI-CH) published in the New England Journal of Medicine [3] - The MI Cancer Seek® assay, an FDA-approved AI-enabled liquid biopsy platform, has shown broad clinical utility for early cancer detection and therapy guidance [4] - New data on sequencing strategies in breast cancer subgroups demonstrates the application of AI-driven molecular insights in treatment decisions [5]